Dr. Sonneveld on Incorporating Genomic Profiling Into Myeloma Management

Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Gene expression profiling should be introduced as a predictor in clinical trials to identify patients with high-risk disease, Sonnevald explains. This represents approximately 15% to 20% of patients with multiple myeloma.

If identified properly, these patients can be selected for different treatment modalities. This is becoming easier, he explains, with the various therapies now FDA approved in this setting.